炎症而非抗瓜氨酸蛋白抗体与RA心血管死亡相关
在无RA的冠心病队列中ACPA患病率低且与全因死亡无关;在RA队列中ACPA阳性与死亡关联经CRP调整后不再显著,而CRP与全因及心血管死亡显著相关。
要点
- 无RA的冠心病患者中ACPA患病率低,与全因死亡无关联
- RA中ACPA阳性与死亡关联主要由CRP解释
- CRP与RA全因及心血管死亡显著相关
核心结论
- 在RA中,ACPA阳性与增加的(心血管)死亡关联主要由CRP解释,强调慢性炎症对心血管结局的影响。
研究设计与样本
- 研究纳入2个冠心病队列(LURIC n=2189患者和656对照;CLARICOR n=959患者)调查无RA的CAD患者ACPA患病率,并纳入2个RA队列(EAC n=764;BARFOT n=794)应用联合模型分析CRP的作用。
主要发现
- 两个CAD队列中ACPA患病率分别为0.9%和4.6%,血清阳性与全因死亡无关联。
- RA中ACPA阳性与全因死亡的关联经CRP调整后不再显著。
- RA中CRP与全因和心血管死亡显著相关(间接效应HR[95%CI]:EAC 1.24[1.14-1.34],BARFOT 1.33[1.24-1.42])。
关键数值与推荐
- ACPA采用商用酶联免疫吸附试验检测。
- 采用多变量Cox比例风险模型研究ACPA与全因死亡的关联。
- RA队列应用联合模型研究CRP在ACPA与(心血管)死亡关联中的作用。
临床怎么用
- RA患者心血管风险管理应重视慢性炎症控制,CRP可能是比ACPA更相关的死亡风险标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anticitrullinated protein antibodies (ACPAs) are associated with increased mortality in patients with rheumatoid arthritis (RA). Previous data suggest ACPAs might be associated with worse disease outcomes in patients without RA with coronary artery disease (CAD). Therefore, we investigated ACPA prevalence and its association with mortality in patients with CAD without RA. Furthermore, the role of systemic inflammation in the relation between ACPAs and mortality was investigated in RA. METHODS: The prevalence of ACPAs in patients with CAD without RA was investigated in 2 CAD cohorts (LUdwigshafen Risk and Cardiovascular Health n = 2189 patients and 656 controls; CLARIthromycin for patients with stable CORonary heart disease n = 959 patients) using a commercial enzyme-linked immunosorbent assay. Multivariable Cox proportional hazards models were performed to investigate the association between ACPAs and all-cause mortality. In 2 RA cohorts (Early Arthritis Clinic [EAC] n = 764; Better Anti-rheumatic Farmaco-therapy [BARFOT] n = 794), joint models were applied to investigate the role of C-reactive protein (CRP) on the association between ACPAs and (cardiovascular) mortality. RESULTS: Average follow-up time in the cohorts ranged between 8.2 and 11.8 years. In both CAD cohorts, ACPA prevalence was low (0.9% and 4.6%), and no association was found between seropositivity and all-cause mortality. In patients with RA, the association between ACPA positivity and all-cause mortality was no longer significant after adjustment for CRP. In contrast, CRP was significantly associated with all-cause and cardiovascular mortality in RA (indirect effect hazard ratio [95% CI]: EAC 1.24 [1.14-1.34], BARFOT 1.33 [1.24-1.42]). CONCLUSIONS: ACPA prevalence is not increased in patients with CAD without RA. In RA, the association between ACPA positivity and increased (cardiovascular) mortality was primarily explained by CRP. This highlights the impact of chronic inflammation on cardiovascular outcomes in RA.
引用
- Derksen VFAM, Lindschou J, Winkel P, et al. Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts. Ann Rheum Dis. 2025. PMID: 41453823. doi:10.1016/j.ard.2025.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。